Cognitive decline in Parkinson disease
Open accessAbstract
Dementia is a frequent problem encountered in advanced stages of Parkinson disease (PD). In recent years, research has focused on the pre-dementia stages of cognitive impairment in PD, including mild cognitive impairment (MCI). Several longitudinal studies have shown that MCI is a harbinger of dementia in PD, although the course is variable, and stabilization of cognition - or even reversal to normal cognition - is not uncommon. In addition to limbic and cortical spread of Lewy pathology, several other mechanisms are likely to contribute to cognitive decline in PD, and a variety of biomarker studies, some using novel structural and functional imaging techniques, have documented in vivo brain changes associated with cognitive impairment. The evidence consistently suggests that low cerebrospinal fluid levels of amyloid-β 42, a marker of comorbid Alzheimer disease (AD), predict future cognitive decline and dementia in PD. Emerging genetic evidence indicates that in addition to the APOE*ε4 allele (an established risk factor for AD), GBA mutations and SCNA mutations and triplications are associated with cognitive decline in PD, whereas the findings are mixed for MAPT polymorphisms. Cognitive enhancing medications have some effect in PD dementia, but no convincing evidence that progression from MCI to dementia can be delayed or prevented is available, although cognitive training has shown promising results.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There are several candidate genetic risk factors that overlap for AD and PD, most notably APOE and MAPT.
“Moreover there are several candidate genetic risk factors that overlap for AD and PD, most notably APOE and MAPT [127].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · see citing works
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653 · see citing works
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · see citing works
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027 · see citing works
Self-citationLitvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams‐Gray, C. H., et al. (2012) · Movement Disorders · doi:10.1002/mds.24893 · Cited by 2,609 · see citing works
Self-citationThe Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., ADENA, M. A., Halliday, G. M., & Morris, J. G. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,245 · see citing works
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029 · see citing works
Healy, D. G., Falchi, M., O’Sullivan, S. S., Bonifati, V., Dürr, A., Bressman, S., Brice, A., Aasly, J. O., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,523 · see citing works
Prevalence and Characteristics of Dementia in Parkinson Disease
Aarsland, D., Andersen, K., Larsen, J. O., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,403 · see citing works
Self-citationMultimodal classification of Alzheimer's disease and mild cognitive impairment
Zhang, D., Wang, Y., Zhou, L., Yuan, H., & Shen, D. G. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.01.008 · Cited by 1,312 · see citing works
Rivastigmine for Dementia Associated with Parkinson's Disease
Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., Deyn, P. P. D., Durif, F., Kulisevsky, J., van Laar, T., Lees, A. J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041470 · Cited by 1,219 · see citing works
Self-citationThe distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort
Williams‐Gray, C. H., Evans, J., Goris, A., Foltynie, T., Ban, M., Robbins, T. W., Brayne, C., Kolachana, B. S., Weinberger, D. R., Sawcer, S. J., et al. (2009) · Brain · doi:10.1093/brain/awp245 · Cited by 970 · see citing works
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies
Irwin, D. J., Lee, V. M. ‐., & Trojanowski, J. Q. (2013) · Nature reviews. Neuroscience · doi:10.1038/nrn3549 · Cited by 875 · see citing works
Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications
Farrer, M. J., Kachergus, J. M., Forno, L. S., Lincoln, S., Wang, D., Hulihan, M., Maraganore, D. M., Gwinn, K. A., Wszołek, Z. K., Dickson, D. W., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10846 · Cited by 699 · see citing works
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort
Williams‐Gray, C. H., Mason, S., Evans, J., Foltynie, T., Brayne, C., Robbins, T. W., & Barker, R. A. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305277 · Cited by 683 · see citing works
Schulz-Schaeffer, W. J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0711-0 · Cited by 627 · see citing works
Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?
Compta, Y., Parkkinen, L., O’Sullivan, S. S., Vandrovcová, J., Holton, J. L., Collins, C., Lashley, T., Kallis, C., Williams, D. R., de Silva, R., et al. (2011) · Brain · doi:10.1093/brain/awr031 · Cited by 585 · see citing works
Cognitive Impairment in Parkinson’s Disease: The Dual Syndrome Hypothesis
Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2012) · Neurodegenerative Diseases · doi:10.1159/000341998 · Cited by 574 · see citing works
Minoshima, S., Foster, N. L., Sima, A. A. F., Frey, K. A., Albin, R. L., & Kuhl, D. E. (2001) · Annals of Neurology · doi:10.1002/ana.1133 · Cited by 560 · see citing works
Bohnen, N. I., Kaufer, D., Ivanco, L. S., Lopresti, B. J., Koeppe, R. A., Davis, J. G., Mathis, C. A., Moore, R. Y., & DeKosky, S. T. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1745 · Cited by 551 · see citing works
Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment
Svenningsson, P., Westman, E., Ballard, C. G., & Aarsland, D. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70152-7 · Cited by 497 · see citing works
Self-citationAarsland, D., Ballard, C. G., Walker, Z., Boström, F., Alves, G. W., Kossakowski, K., Leroi, I., Pozo-Rodriguez, F., Minthon, L., & Londos, E. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70146-2 · Cited by 464 · see citing works
Self-citationGenetic screening for a single common LRRK2 mutation in familial Parkinson's disease
Nichols, W. C., Pankratz, N., Hernandez, D., Paisán-Ruíz, C., Jain, S., Halter, C. A., Michaels, V. E., Reed, T., Rudolph, A., Shults, C. W., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17828-3 · Cited by 457 · see citing works
Katona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445 · see citing works
Emre, M., Tsolaki, M., Bonuccelli, U., Destée, A., TOLOSA, E. S., Kutzelnigg, A., Ceballos-Baumann, A., Zdravkovic, S., Bladström, A., & Jones, R. W. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70194-0 · Cited by 438 · see citing works
Edison, P., Rowe, C. C., Rinne, J. O., Ng, S., Ahmed, I., Kemppainen, N. M., Villemagne, V. L., O'Keefe, G. J., Någren, K., Chaudhuri, К. R., et al. (2008) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.127878 · Cited by 422 · see citing works
Survival and dementia in GBA ‐associated Parkinson's disease: T he mutation matters
Cilia, R., Tùnesi, S., Marotta, G., Cereda, E., Siri, C., Tesei, S., Zecchinelli, A., Canesi, M., Mariani, C. B., Meucci, N., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24777 · Cited by 407 · see citing works
Changes in network activity with the progression of Parkinson's disease
Huang, C. C., Tang, C., Feigin, A., LESSER, M. L., Ma, Y., Pourfar, M., DHAWAN, V. M., & Eidelberg, D. (2007) · Brain · doi:10.1093/brain/awm086 · Cited by 397 · see citing works
Hilker, R., Thomas, A. V., Klein, J. C., Weisenbach, S., Kalbe, E., Burghaus, L., Jacobs, A. H., Herholz, K., & Wd, H. (2005) · Neurology · doi:10.1212/01.wnl.0000191154.78131.f6 · Cited by 383 · see citing works
CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease
Siderowf, A. D., Xie, S. X., Hurtig, H. I., Weintraub, D. A., Duda, J. E., Chen‐Plotkin, A. S., Shaw, L. M. J., Deerlin, V. M. V., Trojanowski, J. Q., & Clark, C. N. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f39a78 · Cited by 379 · see citing works
Self-citationPredictors of dementia in Parkinson disease
Anang, J. B. M., Gagnon, J., Bertrand, J., Romenets, S. R., Latreille, V., Panisset, M., Montplaisir, J. Y., & Postuma, R. B. (2014) · Neurology · doi:10.1212/wnl.0000000000000842 · Cited by 379 · see citing works
Non motor subtypes and Parkinson's disease
Sauerbier, A., Jenner, P. G., Todorova, A., & Chaudhuri, К. R. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.09.027 · Cited by 377 · see citing works
Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET
Shimada, H., Hirano, S., Shinotoh, H., Aotsuka, A., Sato, K., Tanaka, N., Ota, T., Asahina, M., Fukushi, K., Kuwabara, S., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181ab2b58 · Cited by 367 · see citing works
The neurobiological basis of cognitive impairment in Parkinson's disease
Halliday, G. M., Leverenz, J. B., Schneider, J. S., & Adler, C. H. (2014) · Movement Disorders · doi:10.1002/mds.25857 · Cited by 366 · see citing works
Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo
Klein, J. C., Eggers, C., Kalbe, E., Weisenbach, S., Hohmann, C., Vollmar, S., Baudrexel, S., Diederich, N. J., Heiß, W.-D., & Hilker, R. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d55f61 · Cited by 355 · see citing works
Differences in neuropathologic characteristics across the Lewy body dementia spectrum
Ballard, C., Ziabreva, I., Perry, R., Larsen, J. P., O'Brien, J., McKeith, I., Perry, E., & Aarsland, D. (2006) · Neurology · doi:10.1212/01.wnl.0000249130.63615.cc · Cited by 335 · see citing works
Self-citationNonmotor features of Parkinson's disease subtypes
Marras, C., & Chaudhuri, К. R. (2016) · Movement Disorders · doi:10.1002/mds.26510 · Cited by 327 · see citing works
Prognosis of Mild Cognitive Impairment in Early Parkinson Disease: The Norwegian ParkWest Study
Pedersen, K. F., Larsen, J. P., Tysnes, O.-B., & Alves, G. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.2110 · Cited by 315 · see citing works
Cognitive training in Parkinson disease
Leung, I. H. K., Walton, C. C., Hallock, H., Lewis, S. J. G., Valenzuela, M., & Lampit, A. (2015) · Neurology · doi:10.1212/wnl.0000000000002145 · Cited by 313 · see citing works
Caffeine for treatment of Parkinson disease
Postuma, R. B., Lang, A. E., Munhoz, R. P., Charland, K., Pelletier, A., Moscovich, M., Filla, L., Zanatta, D., Romenets, S. R., Altman, R., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318263570d · Cited by 300 · see citing works
Winder‐Rhodes, S., Evans, J., Ban, M., Mason, S., Williams‐Gray, C. H., Foltynie, T., Durán, R., Mencacci, N. E., Sawcer, S. J., & Barker, R. A. (2013) · Brain · doi:10.1093/brain/aws318 · Cited by 290 · see citing works
Parkinson's disease, insulin resistance and novel agents of neuroprotection
Avilés-Olmos, I., Limousin, P. D., Lees, A. J., & Foltynie, T. (2012) · Brain · doi:10.1093/brain/aws009 · Cited by 284 · see citing works
Wang, H.-F., Yu, J., Tang, S., Jiang, T., Tan, C.-C., Meng, X.-F., Wang, C., Tan, M., & Tan, L. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307659 · Cited by 275 · see citing works
Lindqvist, D., Hall, S., Surova, Y., Nielsen, H. M., Janelidze, S., Brundin, L., & Hansson, O. (2013) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2013.07.007 · Cited by 272 · see citing works
Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's disease
Goris, A., Williams‐Gray, C. H., Clark, G. R., Foltynie, T., Lewis, S. J. G., Brown, J., Ban, M., Spillantini, M. G., Compston, A., Burn, D. J., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21192 · Cited by 270 · see citing works
Cognitive performance of GBA mutation carriers with early-onset PD
Alcalay, R. N., Caccappolo, E., Mejia‐Santana, H., Tang, M. X., Rosado, L., Reilly, M. O., Ruiz, D., Ross, B., Verbitsky, M., Kisselev, S., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318253d54b · Cited by 266 · see citing works
Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's
Liu, G., Boot, B. P., Locascio, J. J., Jansen, I. E., Winder‐Rhodes, S., Eberly, S. W., Elbaz, A., Brice, A., Ravina, B. M., van Hilten, J. J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24781 · Cited by 264 · see citing works
Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer’s dementia
Kuhn, J., Hardenacke, K., Lenartz, D., Gruendler, T. O. J., Ullsperger, M., Bartsch, C., Mai, J. K., Zilles, K., Bauer, A., Matusch, A., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.32 · Cited by 262 · see citing works
Mak, E., Su, L., Williams, G. B., Firbank, M., Lawson, R. A., Yarnall, A. J., Duncan, G. W., Owen, A. M., Khoo, T. K., Brooks, D. J., et al. (2015) · Brain · doi:10.1093/brain/awv211 · Cited by 261 · see citing works
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease
Weintraub, D., Mavandadi, S., Mamikonyan, E., Siderowf, A. D., Duda, J. E., Hurtig, H. I., Colcher, A., Horn, S. S., Nazem, S., Ten Have, T. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ebdd79 · Cited by 255 · see citing works
Self-citationMartínez‐Martín, P., Reddy, P., Katzenschlager, R., Antonini, A., Todorova, A., Odin, P., Henriksen, T., Martin, A., Calandrella, D., Rizos, A., et al. (2014) · Movement Disorders · doi:10.1002/mds.26067 · Cited by 252 · see citing works
Longitudinal study of normal cognition in Parkinson disease
Pigott, K., Rick, J., Xie, S. X., Hurtig, H., Chen-Plotkin, A., Duda, J. E., Morley, J. F., Chahine, L. M., Dahodwala, N., Akhtar, R. S., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002001 · Cited by 251 · see citing works
Self-citationNeuroimaging in Parkinson disease: from research setting to clinical practice
Politis, M. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.205 · Cited by 247 · see citing works
Self-citationEhrt, U., Broich, K., Larsen, J. O., Ballard, C. G., & Aarsland, D. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.186239 · Cited by 245 · see citing works
Self-citationCSF biomarkers and clinical progression of Parkinson disease
Hall, S., Surova, Y., Öhrfelt, A., Zetterberg, H., Lindqvist, D., & Hansson, O. (2014) · Neurology · doi:10.1212/wnl.0000000000001098 · Cited by 236 · see citing works
Increased CSF neurogranin concentration is specific to Alzheimer disease
Wellington, H., Paterson, R. W., Portelius, E., Törnqvist, U., Magdalinou, N., Fox, N. C., Blennow, K., Schott, J. M., & Zetterberg, H. (2016) · Neurology · doi:10.1212/wnl.0000000000002423 · Cited by 232 · see citing works
Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases
Gomperts, S. N., Locascio, J. J., Makaretz, S. J., Schultz, A. P., Caso, C., Vasdev, N., Sperling, R. A., Growdon, J. H., Dickerson, B. C., & Johnson, K. A. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3338 · Cited by 228 · see citing works
Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review
Petrou, M., Dwamena, B. A., Foerster, B. R., MacEachern, M., Bohnen, N. I., Müller, M. L. T. M., Albin, R. L., & Frey, K. A. (2015) · Movement Disorders · doi:10.1002/mds.26191 · Cited by 222 · see citing works
Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt–PCP–JNK pathway
Killick, R., Ribe, E. M., Al-Shawi, R., Malik, B., Hooper, C., Fernandes, C., Dobson, R., Nolan, P. M., Lourdusamy, A., Furney, S., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2012.163 · Cited by 222 · see citing works
Quantitative EEG as a predictive biomarker for Parkinson disease dementia
Klassen, B. T., Hentz, J. G., Shill, H. A., Driver‐Dunckley, E. D., Evidente, V. G. H., Sabbagh, M. N., Adler, C. H., & Caviness, J. N. (2011) · Neurology · doi:10.1212/wnl.0b013e318224af8d · Cited by 215 · see citing works
Hanganu, A., Bedetti, C., Degroot, C., Mejia‐Constain, B., Lafontaine, A., Soland, V., Chouinard, S., Bruneau, M., Mellah, S., Belleville, S., et al. (2014) · Brain · doi:10.1093/brain/awu036 · Cited by 214 · see citing works
Fan, Z., Aman, Y., Ahmed, I., Chetelat, G., Landeau, B., Ray Chaudhuri, K., Brooks, D. J., & Edison, P. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.016 · Cited by 212 · see citing works
Hansson, O., Hall, S., Öhrfelt, A., Zetterberg, H., Blennow, K., Minthon, L., Nägga, K., Londos, E., Varghese, S., Majbour, N. K., et al. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt255 · Cited by 208 · see citing works
GBA Variants are associated with a distinct pattern of cognitive deficits in P arkinson's disease
Mata, I. F., Leverenz, J. B., Weintraub, D. A., Trojanowski, J. Q., Chen‐Plotkin, A. S., Deerlin, V. M. V., Ritz, B. R., Rausch, R., Factor, S. A., Wood‐Siverio, C., et al. (2015) · Movement Disorders · doi:10.1002/mds.26359 · Cited by 203 · see citing works
Self-citationAPOE,MAPT, andSNCAGenes and Cognitive Performance in Parkinson Disease
Mata, I. F., Leverenz, J. B., Weintraub, D. A., Trojanowski, J. Q., Hurtig, H. I., Deerlin, V. M. V., Ritz, B. R., Rausch, R., Rhodes, S. L., Factor, S. A., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1455 · Cited by 203 · see citing works
Self-citationReview: Parkinson's disease: from synaptic loss to connectome dysfunction
Bellucci, A., Mercuri, N. B., Venneri, A., Faustini, G., Longhena, F., Pizzi, M., Missale, C., & Spano, P. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12297 · Cited by 203 · see citing works
Donepezil in Parkinson's disease dementia: A randomized, double‐blind efficacy and safety study
Dubois, B., Tolosa, E., Katzenschlager, R., Emre, M., Lees, A. J., Schumann, G., Pourcher, E., Gray, J., Thomas, G., Swartz, J., et al. (2012) · Movement Disorders · doi:10.1002/mds.25098 · Cited by 202 · see citing works
Evolution of mild cognitive impairment in Parkinson disease
Broeders, M., de Bie, R. M. A., Velseboer, D. C., Speelman, J. D., Muslimović, D., & Schmand, B. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31829c5c86 · Cited by 201 · see citing works
Andreassen, O. A., Harbo, H. F., Wang, Y., Thompson, W. K., Schork, A. J., Mattingsdal, M., Zuber, V., Bettella, F., Ripke, S., Kelsoe, J. R., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.195 · Cited by 200 · see citing works
Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease
Bäckström, D. C., Domellöf, M. E., Linder, J., Olsson, B., Öhrfelt, A., Trupp, M., Zetterberg, H., Blennow, K., & Forsgren, L. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1449 · Cited by 197 · see citing works
Regional Multiple Pathology Scores Are Associated with Cognitive Decline in L ewy Body Dementias
Howlett, D. R., Whitfield, D., Johnson, M. A., Attems, J., O'Brien, J. T., Aarsland, D., Lai, M. K. P., Lee, J. H., Chen, C., Ballard, C. G., et al. (2014) · Brain Pathology · doi:10.1111/bpa.12182 · Cited by 196 · see citing works
Self-citationCortical thinning is associated with disease stages and dementia in Parkinson's disease
Zarei, M., Ibarretxe‐Bilbao, N., Compta, Y., Hough, M., Junqué, C., Bargalló, N., Tolosa, E., & Martí, M. J. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304126 · Cited by 192 · see citing works
Clinical features of LRRK2‐associated Parkinson's disease in central Norway
Aasly, J. O., Toft, M., Mata, I. F., Kachergus, J. M., Hulihan, M., White, L. R., & Farrer, M. J. (2005) · Annals of Neurology · doi:10.1002/ana.20456 · Cited by 191 · see citing works
Ibarretxe‐Bilbao, N., Junqué, C., TOLOSA, E. S., Martı́, M. J., Valldeoriola, F., Bargalló, N., & Zarei, M. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06892.x · Cited by 187 · see citing works
Exercise improves cognition in Parkinson's disease: The PRET‐PD randomized, clinical trial
David, F. J., Robichaud, J. A., Leurgans, S. E., Poon, C., Kohrt, W. M., Goldman, J. G., Comella, C. L., Vaillancourt, D. E., & Corcos, D. M. (2015) · Movement Disorders · doi:10.1002/mds.26291 · Cited by 186 · see citing works
Heterogeneity of Cholinergic Denervation in Parkinson's Disease without Dementia
Bohnen, N. I., Müller, M. L. T. M., Kotagal, V., Koeppe, R. A., Kilbourn, M. R., Gilman, S., Albin, R. L., & Frey, K. A. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.60 · Cited by 186 · see citing works
Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia
Gomperts, S. N., Locascio, J. J., Rentz, D. M., Santarlasci, A., Marquié, M., Johnson, K. A., & Growdon, J. H. (2012) · Neurology · doi:10.1212/wnl.0b013e31827b1a07 · Cited by 182 · see citing works
Williams‐Gray, C. H., Hampshire, A., Robbins, T. W., Owen, A. M., & Barker, R. A. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0774-07.2007 · Cited by 180 · see citing works
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
Parnetti, L., Farotti, L., Eusebi, P., Chiasserini, D., Carlo, C. D., Giannandrea, D., Salvadori, N., Lisetti, V., Tambasco, N., Rossi, A., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00053 · Cited by 177 · see citing works
Role of Dopamine in Learning and Memory
Kulisevsky, J. (2000) · Drugs & Aging · doi:10.2165/00002512-200016050-00006 · Cited by 177 · see citing works
Agosta, F., Canu, E., Stefanova, E. D., Sarro, L., Tomić, A., Marković, V., Comı, G., Kostić, V., & Filippi, M. (2013) · Human Brain Mapping · doi:10.1002/hbm.22302 · Cited by 169 · see citing works
Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia
Bereczki, E., Francis, P. T., Howlett, D., Pereira, J. B., Höglund, K., Bogstedt, A., Cedazo‐Minguez, A., Baek, J., Hortobágyi, T., Attems, J., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.04.005 · Cited by 167 · see citing works
Self-citationAttentional control in Parkinson's disease is dependent on COMT val158met genotype
Williams‐Gray, C. H., Hampshire, A., Barker, R., & Owen, A. M. (2008) · Brain · doi:10.1093/brain/awm313 · Cited by 165 · see citing works
L ongitudinal M easurements of C erebrospinal F luid B iomarkers in P arkinson's D isease
Hall, S., Surova, Y., Öhrfelt, A., Study, T. S. B., Blennow, K., Zetterberg, H., & Hansson, O. (2016) · Movement Disorders · doi:10.1002/mds.26578 · Cited by 165 · see citing works
Gonzalez-Redondo, R., García‐García, D., Clavero, P., Gasca‐Salas, C., de Eulate, M. R. G., Zubieta, J. L., Arbizu, J., Obeso, J. A., & Rodríguez‐Oroz, M. (2014) · Brain · doi:10.1093/brain/awu159 · Cited by 163 · see citing works
Ito, K., Nagano‐Saito, A., Kato, T., Arahata, Y., Nakamura, A., Kawasumi, Y., Hatano, K., Abe, Y., Yamada, T., Kachi, T., et al. (2002) · Brain · doi:10.1093/brain/awf134 · Cited by 163 · see citing works
Borght, T. V., Minoshima, S., Giordani, B., Foster, N. L., Frey, K. A., Berent, S., Albin, R. L., Koeppe, R. A., & Kuhl, D. E. (1997) · PubMed · Cited by 160 · see citing works
Functional connectivity and cognitive decline over 3 years in Parkinson disease
Dubbelink, K. T. E. O., Schoonheim, M. M., Deijen, J. B., Twisk, J. W. R., Barkhof, F., & Berendse, H. W. (2014) · Neurology · doi:10.1212/wnl.0000000000001020 · Cited by 160 · see citing works
Combined dementia-risk biomarkers in Parkinson's disease: A prospective longitudinal study
Compta, Y., Pereira, J. B., Ríos, J., Ibarretxe‐Bilbao, N., Junqué, C., Bargalló, N., Cámara, A., Buongiorno, M., Fernández, M., Pont‐Sunyer, C., et al. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.03.009 · Cited by 159 · see citing works
CSF Aβ 42 predicts early-onset dementia in Parkinson disease
Alves, G. W., Lange, J., Blennow, K., Zetterberg, H., Andréasson, U., Førland, M. G. G., Tysnes, O., Larsen, J. O., & Pedersen, K. F. (2014) · Neurology · doi:10.1212/wnl.0000000000000425 · Cited by 157 · see citing works
Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s Disease
Williams‐Gray, C. H., Goris, A., Saiki, M., Foltynie, T., Compston, D. A. S., Sawcer, S. J., & Barker, R. (2009) · Journal of Neurology · doi:10.1007/s00415-009-0119-8 · Cited by 157 · see citing works
Apomorphine treatment in Alzheimer mice promoting amyloid‐β degradation
Himeno, E., Ohyagi, Y., Ma, L., Nakamura, N., Miyoshi, K., Sakae, N., Motomura, K., Soejima, N., Yamasaki, R., Hashimoto, T., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22319 · Cited by 155 · see citing works
Gray and white matter imaging: A biomarker for cognitive impairment in early P arkinson's disease?
Duncan, G. W., Firbank, M., Yarnall, A. J., Khoo, T. K., Brooks, D. J., Barker, R. A., Burn, D. J., & O'Brien, J. T. (2015) · Movement Disorders · doi:10.1002/mds.26312 · Cited by 154 · see citing works
Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course
Setó‐Salvia, N., Pagonabarraga, J., Houlden, H., Pascual‐Sedano, B., Dols‐Icardo, O., Tucci, A., Paisán‐Ruiz, C., Campolongo, A., Antón‐Aguirre, S., Martín, I. R., et al. (2011) · Movement Disorders · doi:10.1002/mds.24045 · Cited by 153 · see citing works
Genetic influences on cognitive decline in Parkinson's disease
Morley, J. F., Xie, S. X., Hurtig, H. I., Stern, M. B., Colcher, A., Horn, S. S., Dahodwala, N. A., Duda, J. E., Weintraub, D. A., Chen‐Plotkin, A. S., et al. (2012) · Movement Disorders · doi:10.1002/mds.24946 · Cited by 152 · see citing works
Self-citationMonitoring of 30 marker candidates in early Parkinson disease as progression markers
Mollenhauer, B., Zimmermann, J., Sixel‐Döring, F., Focke, N. K., Wicke, T., Ebentheuer, J., Schaumburg, M., Lang, E., Trautmann, E., Zetterberg, H., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002651 · Cited by 151 · see citing works
Chahine, L. M., Qiang, J., Ashbridge, E., Minger, J., Yearout, D., Horn, S., Colcher, A., Hurtig, H. I., Lee, V. M.-Y., Van Deerlin, V. M., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1274 · Cited by 150 · see citing works
Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study
Santangelo, G., Vitale, C., Picillo, M., Moccia, M., Cuoco, S., Longo, K., Pezzella, D., di Grazia, A., Erro, R., Pellecchia, M. T., et al. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.08.024 · Cited by 149 · see citing works
Cognitive function in the early phase of Parkinson's disease, a five-year follow-up
Domellöf, M., Ekman, U., Forsgren, L., & Elgh, E. (2015) · Acta Neurologica Scandinavica · doi:10.1111/ane.12375 · Cited by 147 · see citing works
Nombela, C., Rowe, J. B., Winder‐Rhodes, S., Hampshire, A., Owen, A. M., Breen, D. P., Duncan, G. W., Khoo, T. K., Yarnall, A. J., Firbank, M., et al. (2014) · Brain · doi:10.1093/brain/awu201 · Cited by 146 · see citing works
The nucleus basalis of Meynert: A new target for deep brain stimulation in dementia?
Gratwicke, J., Kahan, J., Zrinzo, L. U., Hariz, M. I., Limousin, P. D., Foltynie, T., & Jahanshahi, M. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.09.003 · Cited by 144 · see citing works
Lee, J. E., Cho, K. H., Song, S. K., Kim, H. J., Lee, H. S., Sohn, Y. H., & Lee, P. H. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305062 · Cited by 144 · see citing works
Yong, S. W., Yoon, J., An, Y., & Lee, P. H. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.01977.x · Cited by 142 · see citing works
Dementia Risk in Parkinson Disease
Setó‐Salvia, N., Clarimón, J., Pagonabarraga, J., Pascual‐Sedano, B., Campolongo, A., Combarros, O., Mateo, J. I., Regaña, D., Martínez-Corral, M., Marquié, M., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.17 · Cited by 142 · see citing works
Whitfield, D., Vallortigara, J., Alghamdi, A., Howlett, D. R., Hortobágyi, T., Johnson, M., Attems, J., Newhouse, S., Ballard, C. G., Thomas, A. J., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.015 · Cited by 141 · see citing works
Self-citationGenetic overlap between Alzheimer’s disease and Parkinson’s disease at the MAPT locus
Desikan, R. S., Schork, A. J., Wang, Y., Witoelar, A., Sharma, M., McEvoy, L. K., Holland, D., Brewer, J. B., Chen, C., Thompson, W. K., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.6 · Cited by 141 · see citing works
Self-citationStewart, T., Liu, C., Ginghină, C., Cain, K. C., Auinger, P., Cholerton, B., Shi, M. Y., & Zhang, J. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.12.007 · Cited by 140 · see citing works
Targeting impulsivity in Parkinson’s disease using atomoxetine
Kehagia, A. A., Housden, C. R., Regenthal, R., Barker, R. A., Müller, U., Rowe, J. B., Sahakian, B. J., & Robbins, T. W. (2014) · Brain · doi:10.1093/brain/awu117 · Cited by 139 · see citing works
Pattern of Regional Cortical Thinning Associated with Cognitive Deterioration in Parkinson’s Disease
Pagonabarraga, J., Corcuera‐Solano, I., Vives‐Gilabert, Y., Llebaria, G., García‐Sánchez, C., Pascual‐Sedano, B., Delfino, M., Kulisevsky, J., & Gómez‐Ansón, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054980 · Cited by 138 · see citing works
[11C]PIB binding in Parkinson's disease dementia
Maetzler, W., Reimold, M., Liepelt, I., Solbach, C., Leyhe, T., Schweitzer, K. J., Eschweiler, G. W., Mittelbronn, M. G. A., Gaenslen, A., Uebele, M., et al. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.09.072 · Cited by 137 · see citing works
Reynolds, G., Otto, M. W., Ellis, T. D., & Cronin‐Golomb, A. (2015) · Movement Disorders · doi:10.1002/mds.26484 · Cited by 132 · see citing works
Valera, E., Spencer, B. J., & Masliah, E. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0397-z · Cited by 129 · see citing works
Motor and nonmotor heterogeneity of LRRK2 ‐related and idiopathic Parkinson's disease
Marras, C., Alcalay, R. N., Caspell‐Garcia, C., Coffey, C. S., Chan, P., Duda, J. E., Facheris, M., Fernández‐Santiago, R., Ruiz‐Martínez, J., Mestre, T., et al. (2016) · Movement Disorders · doi:10.1002/mds.26614 · Cited by 128 · see citing works
Hippocampal abnormalities and memory deficits in Parkinson disease
Carlesimo, G. A., Piras, F., Assogna, F., Pontieri, F. E., Caltagirone, C., & Spalletta, G. (2012) · Neurology · doi:10.1212/wnl.0b013e318259e1c5 · Cited by 126 · see citing works
Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo‐controlled study
Mamikonyan, E., Xie, S. X., Melvin, E., & Weintraub, D. A. (2015) · Movement Disorders · doi:10.1002/mds.26236 · Cited by 122 · see citing works
Self-citationAberrant cerebral network topology and mild cognitive impairment in early Parkinson's disease
Pereira, J. B., Aarsland, D., Ginestet, C. E., Lebedev, A. V., Wahlund, L., Simmons, A., Volpe, G., & Westman, E. (2015) · Human Brain Mapping · doi:10.1002/hbm.22822 · Cited by 120 · see citing works
Self-citationPlanning ability in Parkinson's disease is influenced by the COMT val 158 met polymorphism
Foltynie, T., Goldberg, T. E., Lewis, S. J. G., Blackwell, A. D., Kolachana, B. S., Weinberger, D. R., Robbins, T. W., & Barker, R. A. (2004) · Movement Disorders · doi:10.1002/mds.20118 · Cited by 120 · see citing works
Imaging of microglia in patients with neurodegenerative disorders
Politis, M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00096 · Cited by 111 · see citing works
Self-citationFirst appraisal of brain pathology owing to A30P mutant alpha‐synuclein
Seidel, K., Schöls, L. J., Nuber, S., Petrasch‐Parwez, E., Gierga, K., Wszołek, Z. K., Dickson, D. W., Gai, W., Bornemann, A., Rieß, O., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21966 · Cited by 110 · see citing works
Öhrfelt, A., Zetterberg, H., Andersson, K., Persson, R., Secic, D., Brinkmalm, G., Wallin, A., Mulugeta, E., Francis, P. T., Vanmechelen, E., et al. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0527-x · Cited by 109 · see citing works
Self-citationGoldwurm, S., Zini, M., Fonzo, A. D., Gaspari, D. D., Siri, C., Simons, E. J., van Doeselaar, M., Tesei, S., Antonini, A., Canesi, M., et al. (2006) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2006.04.001 · Cited by 108 · see citing works
Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson’s disease patients
Paul, G., Zachrisson, O., Varrone, A., Almqvist, P. M., Jerling, M., Lind, G., Rehncrona, S., Linderoth, B., Bjartmarz, H., Shafer, L. L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79635 · Cited by 107 · see citing works
A large study reveals no association between APOE and Parkinson's disease
Federoff, M., Jimenez‐Rolando, B., Nalls, M. A., & Singleton, A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.02.002 · Cited by 106 · see citing works
A Swedish family with de novo α-synuclein A53T mutation: Evidence for early cortical dysfunction
Puschmann, A., Ross, O. A., Vilariño‐Güell, C., Lincoln, S., Kachergus, J. M., Cobb, S. A., Lindquist, S. G., Nielsen, J. E., Wszołek, Z. K., Farrer, M. J., et al. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2009.06.007 · Cited by 105 · see citing works
Hippocampal volume and white matter disease in the prediction of dementia in Parkinson's disease
Kandiah, N., Zainal, N. H., Narasimhalu, K., Chander, R. J., Ng, A. Y. T., Mak, E., Au, W. L., Sitoh, Y. Y., Nadkarni, N. V., & Tan, L. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.08.024 · Cited by 105 · see citing works
Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease
Oeda, T., Umemura, A., Mori, Y., Tomita, S., Kohsaka, M., Park, K., Inoue, K., Fujimura, H., Hasegawa, H., Sugiyama, H., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.027 · Cited by 103 · see citing works
CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease
Terrelonge, M., Marder, K. S., Weintraub, D. A., & Alcalay, R. N. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0647-x · Cited by 102 · see citing works
Self-citationChahine, L. M., Weintraub, D. A., Hawkins, K. A., Siderowf, A. D., Eberly, S. W., Oakes, D., Seibyl, J. P., Stern, M. B., MAREK, K. L., Jennings, D. L., et al. (2015) · Movement Disorders · doi:10.1002/mds.26373 · Cited by 102 · see citing works
Self-citationAβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia
Petrou, M., Bohnen, N. I., Müller, M. L. T. M., Koeppe, R. A., Albin, R. L., & Frey, K. A. (2012) · Neurology · doi:10.1212/wnl.0b013e3182698d4a · Cited by 101 · see citing works
Cholinergic imaging in dementia spectrum disorders
Roy, R., Niccolini, F., Pagano, G., & Politis, M. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3349-x · Cited by 101 · see citing works
Self-citationChen, B., Fan, G. G., Liu, H., & Wang, S. (2015) · European Journal of Radiology · doi:10.1016/j.ejrad.2015.04.014 · Cited by 98 · see citing works
Biomarkers of cognitive decline in Parkinson's disease
Lin, C., & Wu, R. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.02.010 · Cited by 95 · see citing works
Belarbi, S., Hecham, N., Lesage, S., Kediha, M. I., Smail, N., Benhassine, T., Ysmail-Dahlouk, F., Lohman, E., Benhabyles, B., Hamadouche, T., et al. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.09.003 · Cited by 94 · see citing works
Simonsen, A. H., Kuiperij, H. B., El‐Agnaf, O. M. A., Engelborghs, S., Herukka, S., Parnetti, L., Rektorová, I., Vanmechelen, E., Kapaki, E. N., Verbeek, M. M., et al. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.14.105 · Cited by 94 · see citing works
α‐synuclein genetic variability: A biomarker for dementia in Parkinson disease
Guella, I., Evans, D. M., Szu‐Tu, C., Nosova, E., Bortnick, S., SNCA Cognition Study Group, Goldman, J. G., Dalrymple‐Alford, J. C., Geurtsen, G. J., Litvan, I., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24664 · Cited by 94 · see citing works
Event-related potentials and cognition in Parkinson’s disease: An integrative review
Seer, C., Lange, F., Georgiev, D., Jahanshahi, M., & Kopp, B. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.08.003 · Cited by 94 · see citing works
Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative
Ffytche, D. H., Pereira, J. B., Ballard, C. G., Chaudhuri, К. R., Weintraub, D. A., & Aarsland, D. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314832 · Cited by 94 · see citing works
Self-citationLongitudinal EEG Changes Correlate with Cognitive Measure Deterioration in Parkinson's Disease
Caviness, J. N., Hentz, J. G., Belden, C. M., Shill, H. A., Driver‐Dunckley, E. D., Sabbagh, M. N., Powell, J. J., & Adler, C. H. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-140480 · Cited by 94 · see citing works
Dementia in Parkinson's disease is associated with enhanced mitochondrial complex I deficiency
Gatt, A. P., Duncan, O. F., Attems, J., Francis, P. T., Ballard, C. G., & Bateman, J. E. (2016) · Movement Disorders · doi:10.1002/mds.26513 · Cited by 91 · see citing works
Self-citationRektorová, I., Krajčovičová, L., Mareček, R., & Mikl, M. (2012) · Neurodegenerative Diseases · doi:10.1159/000334765 · Cited by 90 · see citing works
Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism
Pappatà, S., Santangelo, G., Aarsland, D., Vicidomini, C., Longo, K., Brønnick, K., Amboni, M., Erro, R., Vitale, C., Caprio, M. G., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182315259 · Cited by 89 · see citing works
Self-citationvan Dijk, K. D., Bidinosti, M., Weiss, A., Raijmakers, P., Berendse, H. W., & van de Berg, W. D. J. (2014) · European Journal of Neurology · doi:10.1111/ene.12176 · Cited by 88 · see citing works
Borroni, B., Premi, E., Formenti, A., Turrone, R., Alberici, A., Cottini, E., Rizzetti, M. C., Gasparotti, R., & Padovani, A. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.06.013 · Cited by 87 · see citing works
Do Subjective Memory Complaints Herald the Onset of Mild Cognitive Impairment in Parkinson Disease?
Erro, R., Santangelo, G., Barone, P., Picillo, M., Amboni, M., Longo, K., Giordano, F., Moccia, M., Allocca, R., Pellecchia, M. T., et al. (2014) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988714532015 · Cited by 86 · see citing works
Fonseca, L. C., Tedrus, G. M. A. S., Carvas, P. N., & Machado, E. C. F. A. (2013) · Clinical Neurophysiology · doi:10.1016/j.clinph.2013.05.001 · Cited by 85 · see citing works
COPPADIS Study Group, Santos‐García, D., Mir, P., Cubo, E., Vela, L., Rodríguez‐Oroz, M., Martı́, M. J., Arbelo, J. M., Infante, J., Kulisevsky, J., et al. (2016) · BMC Neurology · doi:10.1186/s12883-016-0548-9 · Cited by 83 · see citing works
Different PD-MCI criteria and risk of dementia in Parkinson’s disease: 4-year longitudinal study
Horne, K., Myall, D. J., Livingston, L., Melzer, T. R., Pitcher, T. L., MacAskill, M. R., Geurtsen, G. J., Anderson, T., & Dalrymple‐Alford, J. C. (2016) · npj Parkinson s Disease · doi:10.1038/npjparkd.2015.27 · Cited by 83 · see citing works
Thalamic cholinergic innervation is spared in Alzheimer disease compared to parkinsonian disorders
Kotagal, V., Müller, M. L. T. M., Kaufer, D., Koeppe, R. A., & Bohnen, N. I. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.02.083 · Cited by 83 · see citing works
Cognitive profile of LRRK2‐related Parkinson's disease
Srivatsal, S. R., Cholerton, B., Leverenz, J. B., Wszołek, Z. K., Uitti, R. J., Dickson, D. W., Weintraub, D. A., Trojanowski, J. Q., Deerlin, V. M. V., Quinn, J. F., et al. (2015) · Movement Disorders · doi:10.1002/mds.26161 · Cited by 82 · see citing works
Self-citationGrey Matter Changes in Cognitively Impaired Parkinson's Disease Patients
Rektorová, I., Biundo, R., Mareček, R., Weis, L., Aarsland, D., & Antonini, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085595 · Cited by 81 · see citing works
Self-citationAPOE , MAPT , and COMT and Parkinson’s Disease Susceptibility and Cognitive Symptom Progression
Paul, K. C., Rausch, R., Creek, M. M., Sinsheimer, J. S., Bronstein, J. M., Bordelon, Y. M., & Ritz, B. R. (2016) · Journal of Parkinson s Disease · doi:10.3233/jpd-150762 · Cited by 81 · see citing works
Seibert, T. M., Murphy, E. A., Kaestner, E. J., & Brewer, J. B. (2012) · Radiology · doi:10.1148/radiol.12111280 · Cited by 79 · see citing works
Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease
Stav, A. L., Aarsland, D., Johansen, K. K., Hessen, E., Auning, E., & Fladby, T. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.04.027 · Cited by 76 · see citing works
Self-citationLeverenz, J. B., Watson, G. S., Shofer, J., Zabetian, C. P., Zhang, J., & Montine, T. J. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.10.003 · Cited by 75 · see citing works
Heron, C. J. L., Wright, S. L., Melzer, T. R., Myall, D. J., MacAskill, M. R., Livingston, L., Keenan, R. J., Watts, R., Dalrymple‐Alford, J. C., & Anderson, T. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.40 · Cited by 74 · see citing works
Kurz, M. W., Schlitter, A. M., Klenk, Y., Mueller, T., Larsen, J. P., Aarsland, D., & Dekomien, G. (2007) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988706297737 · Cited by 73 · see citing works
Self-citationMollenhauer, B., Parnetti, L., Rektorová, I., Kramberger, M. G., Pikkarainen, M., Schulz‐Schaeffer, W., Aarsland, D., Svenningsson, P., Farotti, L., Verbeek, M. M., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13390 · Cited by 72 · see citing works
Self-citationSynaptic proteins in CSF relate to Parkinson’s disease stage markers
Bereczki, E., Bogstedt, A., Höglund, K., Tsitsi, P., Brodin, L., Ballard, C., Svenningsson, P., & Aarsland, D. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-017-0008-2 · Cited by 72 · see citing works
Self-citationYe, Z., Rae, C. L., Nombela, C., Ham, T. E., Rittman, T., Jones, P. S., Rodríguez, P. V., Coyle-Gilchrist, I. T. S., Regenthal, R., Altena, E., et al. (2016) · Human Brain Mapping · doi:10.1002/hbm.23087 · Cited by 68 · see citing works
Mitochondrial retrograde signaling regulates neuronal function
Cagin, U., Duncan, O. F., Gatt, A. P., Dionne, M., Sweeney, S. T., & Bateman, J. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505036112 · Cited by 66 · see citing works
Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo‐controlled trial
Weintraub, D. A., Hauser, R. A., Elm, J. J., Pagán, F., Davis, M. D., Choudhry, A., & for the MODERATO Investigators (2016) · Movement Disorders · doi:10.1002/mds.26617 · Cited by 66 · see citing works
Self-citationZhou, B., Wen, M., Yu, W., Zhang, C., & Jiao, L. (2015) · Parkinson s Disease · doi:10.1155/2015/567386 · Cited by 65 · see citing works
CSF proteins and resting-state functional connectivity in Parkinson disease
Campbell, M. C., Koller, J. M., Snyder, A. Z., Buddhala, C., Kotzbauer, P. T., & Perlmutter, J. S. (2015) · Neurology · doi:10.1212/wnl.0000000000001681 · Cited by 65 · see citing works
Positron emission tomography neuroimaging in Parkinson's disease.
Loane, C., & Politis, M. (2011) · PubMed · Cited by 63 · see citing works
Self-citationStriatal and C ortical β‐ A myloidopathy and C ognition in P arkinson's D isease
Shah, N., Frey, K. A., Müller, M. L. T. M., Petrou, M., Kotagal, V., Koeppe, R. A., Scott, P. J. H., Albin, R. L., & Bohnen, N. I. (2015) · Movement Disorders · doi:10.1002/mds.26369 · Cited by 63 · see citing works
Lower cognitive performance in healthy G2019S LRRK2 mutation carriers
Thaler, A., Mirelman, A., Gurevich, T., Simon, E. S., Orr‐Urtreger, A., Marder, K. S., Bressman, S., Giladi, N., Bressman, S., Saunders-Pullman, R. J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182684646 · Cited by 63 · see citing works
Kurz, M. W., Dekomien, G., Nilsen, O. B., Larsen, J. P., Aarsland, D., & Alves, G. W. (2009) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988709332945 · Cited by 62 · see citing works
Self-citationThe Genetic Basis of Cognitive Impairment and Dementia in Parkinson’s Disease
Collins, L., & Williams‐Gray, C. H. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00089 · Cited by 62 · see citing works
Rocha, N. P., Teixeira, A. L., Scalzo, P. L., Barbosa, I. G., de Sousa, M. S., Morato, I. B., Vieira, É. L. M., Christo, P. P., Palotás, A., & Reis, H. J. (2013) · Movement Disorders · doi:10.1002/mds.25752 · Cited by 61 · see citing works
Quantitative EEG Analysis of Executive Dysfunction in Parkinson Disease
Kamei, S., Morita, A., Serizawa, K., Mizutani, T., & Hirayanagi, K. (2010) · Journal of Clinical Neurophysiology · doi:10.1097/wnp.0b013e3181dd4fdb · Cited by 59 · see citing works
Wu, K., O’Keeffe, D., Politis, M., O’Keeffe, G. C., Robbins, T. W., Bose, S. K., Brooks, D. J., Piccini, P. P., & Barker, R. A. (2012) · Brain · doi:10.1093/brain/aws157 · Cited by 57 · see citing works
Self-citationPlasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease
Lim, N., Swanson, C. R., Cherng, H. R. R., Unger, T. L., Xie, S. X., Weintraub, D. A., MAREK, K. L., Stern, M. B., Siderowf, A. D., PARS Investigators, et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.299 · Cited by 57 · see citing works
Self-citationUnfolded protein response is activated in L ewy body dementias
Baek, J., Whitfield, D., Howlett, D. C., Francis, P. T., Bereczki, E., Ballard, C. G., Hortobágyi, T., Attems, J., & Aarsland, D. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12260 · Cited by 55 · see citing works
Self-citationAlcalay, R. N., Mejia‐Santana, H., Tang, M. X., Rakitin, B. C., Rosado, L., Ross, B., Verbitsky, M., Kisselev, S., Louis, E. D., Comella, C. L., et al. (2010) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803390903521018 · Cited by 55 · see citing works
Dopamine receptor mapping with PET imaging in Parkinson’s disease
Niccolini, F., Su, P., & Politis, M. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7302-2 · Cited by 54 · see citing works
Self-citationKo, W. K. D., Camus, S. M. J., Li, Q., Yang, J., McGuire, S., Pioli, E. Y., & Bézard, E. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.012 · Cited by 53 · see citing works
Relationship Between Slowing of the EEG and Cognitive Impairment in Parkinson Disease
Morita, A., Kamei, S., & Mizutani, T. (2011) · Journal of Clinical Neurophysiology · doi:10.1097/wnp.0b013e3182273211 · Cited by 52 · see citing works
Compta, Y., Ibarretxe‐Bilbao, N., Pereira, J. B., Junqué, C., Bargalló, N., TOLOSA, E. S., Valldeoriola, F., Muñoz, E., Cámara, A., Buongiorno, M., et al. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.04.028 · Cited by 52 · see citing works
Winder‐Rhodes, S., Hampshire, A., Rowe, J. B., Peelle, J. E., Robbins, T. W., Owen, A. M., & Barker, R. A. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.006 · Cited by 52 · see citing works
Cognitive dysfunction in Tunisian LRRK2 associated Parkinson’s disease
Sassi, S. B., Nabli, F., Hentati, E., Nahdi, H., Trabelsi, M., Ayed, H. B., Amouri, R., Duda, J. E., Farrer, M. J., & Hentati, F. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.10.009 · Cited by 50 · see citing works
Somme, J. H., Gómez‐Esteban, J. C., Molano, A., Tijero, B., Lezcano, E., & Zarranz, J. J. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.07.047 · Cited by 50 · see citing works
Nie, K., Zhang, Y., Gan, R., Wang, L., Zhao, J., Huang, Z., Tang, H., & Wang, L. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.02.024 · Cited by 49 · see citing works
Cholinergic and perfusion brain networks in Parkinson disease dementia
Colloby, S. J., McKeith, I. G., Burn, D. J., Wyper, D. J., O'Brien, J. T., & Taylor, J. (2016) · Neurology · doi:10.1212/wnl.0000000000002839 · Cited by 48 · see citing works
Diabetes, Gray Matter Loss, and Cognition in the Setting of Parkinson Disease
Petrou, M., Davatzikos, C. A., Hsieh, M., Foerster, B. R., Albin, R. L., Kotagal, V., Müller, M. L. T. M., Koeppe, R. A., Herman, W. H., Frey, K. A., et al. (2016) · Academic Radiology · doi:10.1016/j.acra.2015.07.014 · Cited by 48 · see citing works
BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease
Białecka, M. A., Kurzawski, M., Roszmann, A., Robowski, P., Sitek, E. J., Honczarenko, K., Mak, M., Deptuła-Jarosz, M., Gołąb-Janowska, M., Droździk, M., et al. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2013.12.051 · Cited by 47 · see citing works
Skogseth, R. E., Brønnick, K., Pereira, J. B., Mollenhauer, B., Weintraub, D. A., Fladby, T., & Aarsland, D. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-150682 · Cited by 46 · see citing works
Self-citationMapping Cortical Atrophy in Parkinson's Disease Patients with Dementia
Hwang, K., Beyer, M. K., Green, A. E., Chung, C., Thompson, P. M., Janvin, C. C., Larsen, J. O., Aarsland, D., & Apostolova, L. G. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-120151 · Cited by 42 · see citing works
Self-citationBrain-derived neurotrophic factor G196A polymorphism and clinical features in Parkinson’s disease
Gao, L., Diaz-Corrales, F. J. J., Carrillo, F., Díaz‐Martín, J., Cáceres‐Redondo, M. T., Carballo, M., Palomino, A., López‐Barneo, J., & Mir, P. (2010) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2009.01253.x · Cited by 40 · see citing works
Mood and cognition in leucine‐rich repeat kinase 2 G2019S Parkinson's disease
Shanker, V., Groves, M., Heiman, G. A., Palmese, C. A., Saunders-Pullman, R. J., Ozelius, L. J., Raymond, D., & Bressman, S. (2011) · Movement Disorders · doi:10.1002/mds.23746 · Cited by 40 · see citing works
Unravelling the nonmotor mysteries of Parkinson disease
Chaudhuri, К. R., & Sauerbier, A. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.236 · Cited by 40 · see citing works
Recent imaging advances in neurology
Rocchi, L., Niccolini, F., & Politis, M. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7711-x · Cited by 39 · see citing works
Self-citationApomorphine: A potential modifier of amyloid deposition in Parkinson's disease?
Yarnall, A. J., Lashley, T., Ling, H., Lees, A. J., Coleman, S. Y., O’Sullivan, S. S., Compta, Y., Révész, T., & Burn, D. J. (2015) · Movement Disorders · doi:10.1002/mds.26422 · Cited by 37 · see citing works
Marquié, M., Locascio, J. J., Rentz, D. M., Becker, J. A., Hedden, T., Johnson, K. A., Growdon, J. H., & Gomperts, S. N. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0052-7 · Cited by 37 · see citing works
Correlation of EEG Slowing with Cognitive Domains in Nondemented Patients with Parkinson's Disease
Zimmermann, R., Gschwandtner, U., Hatz, F., Schindler, C. J. A., Bousleiman, H., Ahmed, S., Hardmeier, M., Meyer, A., Calabrese, P., & Fuhr, P. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000370110 · Cited by 37 · see citing works
Vorovenci, R. J., & Antonini, A. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1113131 · Cited by 33 · see citing works
Implication of Green Tea as a Possible Therapeutic Approach for Parkinson Disease
Jurado-Coronel, J. C., Ávila-Rodriguez, M., Echeverrı́a, V., Hidalgo‐Lanussa, O., González, J., Aliev, G. M., & Barreto, G. E. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666160202125519 · Cited by 32 · see citing works
Apolipoprotein E ε4 does not affect cognitive performance in patients with Parkinson's disease
Mengel, D., Dams, J., Ziemek, J., Becker, J., Balzer‐Geldsetzer, M., Hilker, R., Baudrexel, S., Kalbe, E., Schmidt, N., Witt, K., et al. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.04.013 · Cited by 32 · see citing works
Liu, Z., Guo, J., Wang, Y., Li, K., Kang, J.-F., Wei, Y., Sun, Q., Xu, Q., Xu, C., Yan, X., et al. (2016) · Scientific Reports · doi:10.1038/srep19021 · Cited by 31 · see citing works
An Update of the Impact of Deep Brain Stimulation on Non Motor Symptoms in Parkinson's Disease
Klingelhoefer, L., Samuel, M., Chaudhuri, К. R., & Ashkan, K. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-130273 · Cited by 30 · see citing works
Svetel, M. V., Pekmezovic, T. D., Marković, V., Novaković, I. V., Dobričić, V., Djuric, G., Stefanova, E. D., & Kostić, V. (2013) · European Neurology · doi:10.1159/000352033 · Cited by 30 · see citing works
Flagged first, then by citations
Research works printed but not linked: 6
- [68]Mata IFAPOE MAPT, and SNCA genes and cognitive performance in Parkinson disease JAMA Neurol 71 1405 1412 2014 25178429 PMC4227942
- [102]Hall S Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson’s disease Mov. Disord 31 898 905 2016 26878815 PMC5067556
- [146]Shinotoh H Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson’s disease and progressive supranuclear palsy Ann. Neurol 46 62 69 1999 10401781
- [157]Shah N Striatal and cortical β-amyloidopathy and cognition in Parkinson’s disease Mov. Disord 31 111 117 2016 26380951 PMC4724301
- [191]Martinez-Martin P EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease Mov. Disord 30 510 516 2015 25382161
- [193]Reynolds GO Otto MW Ellis TD Cronin-Golomb A The therapeutic potential of exercise to improve mood, cognition, and sleep in Parkinson’s disease Mov. Disord 31 23 38 2016 26715466 PMC4724300
Cited by
Sorted by citations
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329 · see citing works
“Moreover there are several candidate genetic risk factors that overlap for AD and PD, most notably APOE and MAPT [127].”
BackgroundHallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States
Mattson, M. P., & Arumugam, T. V. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.011 · Cited by 1,242 · see citing works
Parkinson’s disease: etiopathogenesis and treatment
Jankovic, J. J., & Tan, E. K. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322338 · Cited by 1,185 · see citing works
Allocati, N., Masulli, M., Di Ilio, C., & Federici, L. (2018) · Oncogenesis · doi:10.1038/s41389-017-0025-3 · Cited by 625 · see citing works
A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward
Belloy, M. E., Napolioni, V., & Greicius, M. D. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.056 · Cited by 570 · see citing works
Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?
Jellinger, K. A., & Korczyn, A. D. (2018) · BMC Medicine · doi:10.1186/s12916-018-1016-8 · Cited by 386 · see citing works
Bee Venom: Overview of Main Compounds and Bioactivities for Therapeutic Interests
Wehbe, R., Frangieh, J., Rima, M., Obeid, D. E., Sabatier, J., & Fajloun, Z. (2019) · Molecules · doi:10.3390/molecules24162997 · Cited by 373 · see citing works
Dynamic functional connectivity changes associated with dementia in Parkinson’s disease
Fiorenzato, E., Strafella, A. P., Kim, J., Schifano, R., Weis, L., Antonini, A., & Biundo, R. (2019) · Brain · doi:10.1093/brain/awz192 · Cited by 306 · see citing works
Czubowicz, K., Jęśko, H. M., Wencel, P. L., Lukiw, W. J., & Strosznajder, R. P. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1448-3 · Cited by 296 · see citing works
Network connectivity determines cortical thinning in early Parkinson’s disease progression
Yau, Y. H. C., Zeighami, Y., Baker, T. E., Larcher, K. M.-H., Vainik, U., Dadar, M., Fonov, V., Hagmann, P., Griffa, A., Mišić, B., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02416-0 · Cited by 271 · see citing works
Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Jellinger, K. A. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1821-9 · Cited by 265 · see citing works
The Pharmacological Action of Kaempferol in Central Nervous System Diseases: A Review
dos Santos, J. S., Cirino, J. P. G., Carvalho, P. D. O., & Ortega, M. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.565700 · Cited by 258 · see citing works
Structure–function coupling in macroscale human brain networks
Fotiadis, P., Parkes, L., Davis, K. A., Satterthwaite, T. D., Shinohara, R. T., & Bassett, D. S. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-024-00846-6 · Cited by 249 · see citing works
18F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment
Meyer, P. T., Frings, L., Rücker, G., & Hellwig, S. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186403 · Cited by 251 · see citing works
Microglia Response During Parkinson’s Disease: Alpha-Synuclein Intervention
Ferreira, S. A., & Romero‐Ramos, M. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00247 · Cited by 220 · see citing works
Wang, Y., Hu, J., Wu, S., Fleishman, J. S., Li, Y., Xu, Y.-S., Zou, W., Wang, J., Feng, Y., Chen, J., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01720-0 · Cited by 218 · see citing works
Schulz, J., Pagano, G., Bonfante, J. A. F., Wilson, H., & Politis, M. (2018) · Brain · doi:10.1093/brain/awy072 · Cited by 209 · see citing works
Self-citationCastelli, V., Benedetti, E., Antonosante, A., Catanesi, M., Pitari, G., Ippoliti, R., Cimini, A., & d’Angelo, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00132 · Cited by 211 · see citing works
Chidambaram, S. B., Essa, M. M., Rathipriya, A. G., Bishir, M., Ray, B., Mahalakshmi, A. M., Tousif, A. H., Sakharkar, M. K., Kashyap, R. S., Friedland, R. P., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107988 · Cited by 204 · see citing works
The Gut-Brain Axis in Parkinson’s Disease: Possibilities for Food-Based Therapies
Perez-Pardo, P., Kliest, T., Dodiya, H. B., Broersen, L. M., Garssen, J., Keshavarzian, A., & Kraneveld, A. D. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.042 · Cited by 203 · see citing works
“Although PD is generally considered as a movement disorder, it has long been recognized that the symptoms go beyond motor dysfunction since PD patients very often develop non-motor symptoms, including cognitive impairment (Aarsland et al., 2017), hyposmia (Haehner et al.”
Backgroundda Silva, F. C., Iop, R. D. R., de Oliveira, L. C., Boll, A. M., de Alvarenga, J. G. S., Gutierres Filho, P. J. B., de Melo, L. M. A. B., Xavier, A. J., & da Silva, R. (2018) · PLOS ONE · doi:10.1371/journal.pone.0193113 · Cited by 189 · see citing works
Phytochemicals and cognitive health: Are flavonoids doing the trick?
Bakoyiannis, I., Daskalopoulou, A., Pergialiotis, V., & Perrea, D. N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.086 · Cited by 186 · see citing works
An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders
Ashton, N. J., Hye, A., Rajkumar, A. P., Leuzy, A., Snowden, S. G., Suárez‐Calvet, M., Karikari, T. K., Schöll, M., Joie, R. L., Rabinovici, G. D., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0348-0 · Cited by 182 · see citing works
Self-citationLiu, G., Locascio, J. J., Corvol, J., Boot, B. P., Liao, Z., Page, K., Franco, D., Burke, K., Jansen, I. E., Lipsanopoulos, A. T. T., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30122-9 · Cited by 174 · see citing works
Rosario, D., Bidkhori, G., Lee, S., Bedarf, J., Hildebrand, F., Le Chatelier, E., Uhlen, M., Ehrlich, S. D., Proctor, G., Wüllner, U., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108807 · Cited by 167 · see citing works
Postural Instability in Parkinson’s Disease: A Review
Palakurthi, B., & Burugupally, S. P. (2019) · Brain Sciences · doi:10.3390/brainsci9090239 · Cited by 165 · see citing works
The Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease
Yang, D., Zhao, D., Ali Shah, S. Z., Wu, W., Lai, M., Zhang, X., Li, J., Guan, Z., Zhao, H., Li, W., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01155 · Cited by 162 · see citing works
Acetylcholine bidirectionally regulates learning and memory
Huang, Q., Liao, C., Ge, F., Ao, J., & Liu, T. (2022) · Journal of Neurorestoratology · doi:10.1016/j.jnrt.2022.100002 · Cited by 165 · see citing works
Rai, S. N., Birla, H., Singh, S. S., Zahra, W., Patil, R. R., Jadhav, J. P., Gedda, M. R., & Singh, S. P. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00421 · Cited by 161 · see citing works
Network imaging biomarkers: insights and clinical applications in Parkinson's disease
Schindlbeck, K. A., & Eidelberg, D. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30169-8 · Cited by 163 · see citing works
Role of Oxidative Stress in Blood–Brain Barrier Disruption and Neurodegenerative Diseases
Kim, S., Jung, U. J., & Kim, S. R. (2024) · Antioxidants · doi:10.3390/antiox13121462 · Cited by 173 · see citing works
The Free-movement pattern Y-maze: A cross-species measure of working memory and executive function
Cleal, M., Fontana, B. D., Ranson, D. C., McBride, S. D., Swinny, J. D., Redhead, E. S., & Parker, M. O. (2020) · Behavior Research Methods · doi:10.3758/s13428-020-01452-x · Cited by 147 · see citing works
Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine
Iarkov, A., Barreto, G. E., Grizzell, J. A., & Echeverrı́a, V. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00004 · Cited by 140 · see citing works
Amyloid-β and Parkinson’s disease
Kings Parcog groupMDS Nonmotor study group, Lim, E. W., Aarsland, D., Ffytche, D. H., Taddei, R. N., van Wamelen, D. J., Wan, Y.-M., Tan, E. K., & Chaudhuri, К. R. (2018) · Journal of Neurology · doi:10.1007/s00415-018-9100-8 · Cited by 137 · see citing works
Self-citationInternational Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease
Laansma, M. A., Bright, J. K., Al–Bachari, S., Anderson, T., Ard, T. D., Assogna, F., Baquero, K., Berendse, H. W., Blair, J. C., Cendes, F., et al. (2021) · Movement Disorders · doi:10.1002/mds.28706 · Cited by 127 · see citing works
Self-citationLiu, G., Peng, J., Liao, Z., Locascio, J. J., Corvol, J.-C., Zhu, F., Dong, X., Maple-Grødem, J., Campbell, M. C., Elbaz, A., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00847-6 · Cited by 127 · see citing works
Diabetes and Cognitive Impairment: A Role for Glucotoxicity and Dopaminergic Dysfunction
Pignalosa, F. C., Desiderio, A., Mirra, P., Nigro, C., Perruolo, G., Ulianich, L., Formisano, P., Bèguinot, F., Miele, C., Napoli, R., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212366 · Cited by 129 · see citing works
Russell, M. W. W., Chung, W. K., Kaltman, J. R., & Miller, T. A. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.006906 · Cited by 125 · see citing works
Dysfunctional Limbic Circuitry Underlying Freezing of Gait in Parkinson’s Disease
Gilat, M., Martens, K. A. E., Miranda-Domínguez, Ó., Arpan, I., Shine, J. M., Mancini, M., Fair, D. A., Lewis, S. J. G., & Horak, F. B. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.01.044 · Cited by 123 · see citing works
Mild cognitive impairment in Parkinson’s disease: the Parkinson’s disease cognitive study (PACOS)
Monastero, R., Cicero, C. E., Baschi, R., Davì, M., Luca, A., Restivo, V., Zangara, C., Fierro, B., Zappia, M., & Nicoletti, A. S. Q. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8800-4 · Cited by 122 · see citing works
Cognition-Oriented Treatments for Older Adults: a Systematic Overview of Systematic Reviews
Gavelin, H. M., Lampit, A., Hallock, H., Sabatés, J., & Bahar‐Fuchs, A. (2020) · Neuropsychology Review · doi:10.1007/s11065-020-09434-8 · Cited by 122 · see citing works
Innate and adaptive immune responses in Parkinson's disease
Schonhoff, A. M., Williams, G. P., Wallen, Z. D., Standaert, D. G., & Harms, A. S. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.006 · Cited by 115 · see citing works
Jung, N., Park, C., Kim, M., Lee, P., Sohn, Y., & Chang, J. W. (2019) · Journal of Neurosurgery · doi:10.3171/2018.2.jns172514 · Cited by 93 · see citing works
Cunningham, J., Broglio, S., O'Grady, M., & Wilson, F. (2020) · Journal of athletic training · doi:10.4085/1062-6050-297-18 · Cited by 99 · see citing works
Primary cilia and ciliary signaling pathways in aging and age-related brain disorders
Ma, R., Kutchy, N. A., Chen, L., Meigs, D. D., & Hu, G. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105607 · Cited by 114 · see citing works
The Relevance of Insulin Action in the Dopaminergic System
Fiory, F., Perruolo, G., Cimmino, I., Cabaro, S., Pignalosa, F. C., Miele, C., Bèguinot, F., Formisano, P., & Oriente, F. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00868 · Cited by 114 · see citing works
Current Status of microRNA-Based Therapeutic Approaches in Neurodegenerative Disorders
Paul, S., Bravo-Vázquez, L. A., Uribe, S. P., Reyes‐Pérez, P., & Sharma, A. K. (2020) · Cells · doi:10.3390/cells9071698 · Cited by 104 · see citing works
Wang, Y., Gao, L., Chen, J., Li, Q., Huo, L., Wang, Y., Wang, H., & Du, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.757161 · Cited by 106 · see citing works
White matter abnormalities in the corpus callosum with cognitive impairment in Parkinson disease
Bledsoe, I. O., Stebbins, G. T., Merkitch, D., & Goldman, J. G. (2018) · Neurology · doi:10.1212/wnl.0000000000006646 · Cited by 99 · see citing works
Therapy of Parkinson's Disease Subtypes
Marras, C., Chaudhuri, К. R., Titova, N., & Mestre, T. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00894-7 · Cited by 97 · see citing works
An overview of sleep and circadian dysfunction in Parkinson's disease
Mantovani, S., Smith, S. S., Gordon, R., & O’Sullivan, J. D. (2018) · Journal of Sleep Research · doi:10.1111/jsr.12673 · Cited by 97 · see citing works
Gray Matter Changes in Parkinson’s and Alzheimer’s Disease and Relation to Cognition
Krajčovičová, L., Klobušiaková, P., & Rektorová, I. (2019) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-019-1006-z · Cited by 96 · see citing works
Halim, A., Qu, K.-Y., Zhang, X.-F., & Huang, N. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00490 · Cited by 95 · see citing works
Recent advances in Lewy body dementia: A comprehensive review
Prasad, S., Katta, M. R., Abhishek, S., Sridhar, R., Valisekka, S. S., Hameed, M., Kaur, J., & Walia, N. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101441 · Cited by 100 · see citing works
Hölscher, C. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109952 · Cited by 94 · see citing works
Motoric Cognitive Risk Syndrome: Association with Incident Dementia and Disability
Doi, T., Shimada, H., Makizako, H., Tsutsumimoto, K., Verghese, J., & Suzuki, T. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170195 · Cited by 93 · see citing works
Meta-Analysis of Cognition in Parkinson’s Disease Mild Cognitive Impairment and Dementia Progression
Wallace, E. R., Segerstrom, S. C., van Horne, C. G., Schmitt, F. A., & Koehl, L. (2021) · Neuropsychology Review · doi:10.1007/s11065-021-09502-7 · Cited by 98 · see citing works
Treatment of Parkinson’s Disease with Cognitive Impairment: Current Approaches and Future Directions
Sun, C. E., & Armstrong, M. J. (2021) · Behavioral Sciences · doi:10.3390/bs11040054 · Cited by 95 · see citing works
Pimavanserin: Potential Treatment For Dementia-Related Psychosis
Cummings, J. L., Ballard, C. G., Tariot, P. N., Owen, R., Foff, E. P., Youakim, J. M., Norton, J., & Stankovic, S. (2018) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.29 · Cited by 89 · see citing works
Self-citationManenti, R., Cotelli, M. S., Cobelli, C., Gobbi, E., Brambilla, M., Rusich, D., Alberici, A., Padovani, A., Borroni, B., & Cotelli, M. (2018) · Brain stimulation · doi:10.1016/j.brs.2018.07.046 · Cited by 91 · see citing works
Nicoletti, A. S. Q., Luca, A., Baschi, R., Cicero, C. E., Mostile, G., Davì, M., Pilati, L., Restivo, V., Zappia, M., & Monastero, R. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00021 · Cited by 88 · see citing works
Homayoun, H. (2018) · Annals of Internal Medicine · doi:10.7326/aitc201809040 · Cited by 87 · see citing works
Singh, B., Covelo, A., Martell-Martinez, H. A., Nanclares, C., Sherman, M. A., Okematti, E., Meints, J. P., Teravskis, P. J., Gallardo, C., Savonenko, A. V., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02032-w · Cited by 84 · see citing works
Cognition in Parkinson's Disease
O’Callaghan, C., & Lewis, S. J. G. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.05.002 · Cited by 85 · see citing works
Xiao, G., Song, Y., Zhang, Y., Xing, Y., Zhao, H., Xie, J., Xu, S., Gao, F., Wang, M., Xing, G., et al. (2019) · ACS Sensors · doi:10.1021/acssensors.9b00182 · Cited by 84 · see citing works
In Pursuit of Healthy Aging: Effects of Nutrition on Brain Function
Melzer, T. M., Manosso, L. M., Yau, S., Gil‐Mohapel, J., & Brocardo, P. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22095026 · Cited by 90 · see citing works
Hosseinzadeh, M., Gorji, A., Jouzdani, A. F., Rezaeijo, S. M., Rahmim, A., & Salmanpour, M. R. (2023) · Diagnostics · doi:10.3390/diagnostics13101691 · Cited by 83 · see citing works
Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease
Melzer, T. R., Stark, M. R., Keenan, R. J., Myall, D. J., MacAskill, M. R., Pitcher, T. L., Livingston, L., Grenfell, S., Horne, K., Young, B., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00391 · Cited by 79 · see citing works
Zhang, Q., Hu, J., Wei, L., Jia, Y., & Jin, Y. (2019) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2019.04.005 · Cited by 80 · see citing works
Leta, V., Chaudhuri, К. R., Milner, O., Chung‐Faye, G., Metta, V., Pariante, C. M., & Borsini, A. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.07.026 · Cited by 77 · see citing works
Guo, J., Yue, F., Song, D., Bousset, L., Liang, X., Tang, J., Yuan, L., Li, W., Melki, R., Tang, Y. C., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03369-x · Cited by 74 · see citing works
Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?
Heinzel, S., Berg, D., Binder, S., Ebersbach, G., Hickstein, L., Herbst, H., Lorrain, M., Wellach, I., Maetzler, W., Petersen, G., et al. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00500 · Cited by 75 · see citing works
Beyond Haemostasis and Thrombosis: Platelets in Depression and Its Co-Morbidities
Izzi, B., Tirozzi, A., Cerletti, C., Donati, M. B., de Gaetano, G., Hoylaerts, M., Iacoviello, L., & Gialluisi, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228817 · Cited by 75 · see citing works
Hirano, S. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00301-7 · Cited by 72 · see citing works
Neuroimaging in Parkinson’s disease dementia: connecting the dots
Weil, R. S., Hsu, J. K., Darby, R. R., Soussand, L., & Fox, M. D. (2019) · Brain Communications · doi:10.1093/braincomms/fcz006 · Cited by 71 · see citing works
Gargouri, F., Galléa, C., Mongin, M., Pyatigorskaya, N., Valabrègue, R., Ewenczyk, C., Sarazin, M., Yahia‐Cherif, L., Vidailhet, M., & Lehéricy, S. (2018) · Movement Disorders · doi:10.1002/mds.27561 · Cited by 71 · see citing works
Jones, J. D., Rahmani, E., Garcia, E., & Jacobs, J. P. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.01.009 · Cited by 71 · see citing works
Vallée, A., Vallée, J.-N., & Lecarpentier, Y. (2021) · Cells · doi:10.3390/cells10020230 · Cited by 71 · see citing works
Computerized cognitive training in Parkinson’s disease: A systematic review and meta-analysis
Gavelin, H. M., Domellöf, M. E., Leung, I. H. K., Neely, A. S., Launder, N. H., Nategh, L., Finke, C., & Lampit, A. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101671 · Cited by 71 · see citing works
Feleke, R., Reynolds, R. H., Smith, A. M., Tilley, B. S., Taliun, S. A. G., Hardy, J., Matthews, P. M., Gentleman, S., Owen, D. R., Johnson, M. R., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02343-x · Cited by 68 · see citing works
Nosrani, E. A., Tamtaji, O. R., Alibolandi, Z., Sarkar, P., Ghazanfari, M., Tameh, A. A., Taghizadeh, M., Banikazemi, Z., Hadavi, R., & Taheri, M. N. (2020) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2020.1833917 · Cited by 69 · see citing works
Redefining Non-Motor Symptoms in Parkinson’s Disease
Peña-Zelayeta, L., Delgado-Minjares, K. M., Villegas-Rojas, M. M., León‐Arcia, K., Santiago-Balmaseda, A., Andrade-Guerrero, J., Pérez-Segura, I., Ortega‐Robles, E., Soto-Rojas, L. O., & Arias-Carrión, Ó. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15050172 · Cited by 76 · see citing works
Rosário, D., Borén, J., Uhlén, M., Proctor, G., Aarsland, D., Mardinoğlu, A., & Shoaie, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00716 · Cited by 66 · see citing works
Self-citationRadad, K., Moldzio, R., Krewenka, C., Kranner, B., & Rausch, W. (2023) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2023.00036 · Cited by 68 · see citing works
Neuromicrobiology: How Microbes Influence the Brain
de la Fuente‐Núñez, C., Meneguetti, B. T., Franco, O. L., & Lu, T. K. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00373 · Cited by 68 · see citing works
Assessment and Management of Neuropsychiatric Symptoms in Parkinson’s Disease
Mueller, C., Rajkumar, A. P., Wan, Y.-M., Velayudhan, L., Ffytche, D. H., Chaudhuri, К. R., & Aarsland, D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0540-6 · Cited by 68 · see citing works
Self-citationQu, W., Yuan, B., Li, R., Liu, Q., Zhang, X., Cui, R., Yang, W., & Li, B. (2020) · Cell Proliferation · doi:10.1111/cpr.12959 · Cited by 64 · see citing works
Pan, W., Liu, P., Ma, D., & Yang, J. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03988-w · Cited by 67 · see citing works
Lasaponara, S., Marson, F., Doricchi, F., & Cavallo, M. (2021) · Brain Science · doi:10.3390/brainsci11050528 · Cited by 54 · see citing works
The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson’s Disease
Mori, A., Chen, J., Uchida, S., Durlach, C., King, S. M., & Jenner, P. G. (2022) · Molecules · doi:10.3390/molecules27072366 · Cited by 66 · see citing works
Wang, Y., Wu, S., Li, Q., Lang, W., Li, W., Jiang, X., Wan, Z., Chen, J., & Wang, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.977521 · Cited by 66 · see citing works
Creese, B., Bell, E., Johar, I., Francis, P. T., Ballard, C. G., & Aarsland, D. (2017) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32549 · Cited by 66 · see citing works
Self-citationTherapeutic Potential of Ursolic Acid to Manage Neurodegenerative and Psychiatric Diseases
Ramos-Hryb, A. B., Pazini, F. L., Kaster, M. P., & Rodrigues, A. L. S. (2017) · CNS Drugs · doi:10.1007/s40263-017-0474-4 · Cited by 66 · see citing works
Adenzato, M., Manenti, R., Enrici, I., Gobbi, E., Brambilla, M., Alberici, A., Cotelli, M. S., Padovani, A., Borroni, B., & Cotelli, M. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-018-0141-9 · Cited by 67 · see citing works
Zhang, R., Wang, S., Huang, X., Yang, Y., Fan, H., Yang, F., Li, J., Dong, X., Feng, S., Anbu, P., et al. (2019) · Analytica Chimica Acta · doi:10.1016/j.aca.2019.10.012 · Cited by 66 · see citing works
Garcia, P., Jürgens‐Wemheuer, W., Uriarte Huarte, O., Michelucci, A., Masuch, A., Brioschi, S., Weihofen, A., Koncina, E., Coowar, D., Heurtaux, T., et al. (2022) · Glia · doi:10.1002/glia.24149 · Cited by 65 · see citing works
Guo, Z., Ruan, Z., Zhang, D., Liu, X., Hou, L., & Wang, Q. (2021) · Chemosphere · doi:10.1016/j.chemosphere.2021.132982 · Cited by 65 · see citing works
Serotonin, β‐amyloid, and cognition in Parkinson disease
Kotagal, V., Spino, C., Bohnen, N. I., Koeppe, R., & Albin, R. L. (2018) · Annals of Neurology · doi:10.1002/ana.25236 · Cited by 64 · see citing works
Guo, Y., Liu, F., Hou, X., Li, J., Cao, X., Tan, L., Wang, J., & Yu, J. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09757-9 · Cited by 68 · see citing works
Sampedro, F., Pérez‐González, R., Martínez‐Horta, S., Marín‐Lahoz, J., Pagonabarraga, J., & Kulisevsky, J. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.04.009 · Cited by 62 · see citing works
- Authors
- Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C.
- Affiliations
- King's College London (GB)
- Corresponding author
- Aarsland, Dag
- Venue
- Nature Reviews Neurology
- Published
- 2017-03-03
- Volume
- 13
- Issue
- 4
- Pages
- 217-231
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC5643027
- OpenAlex
- W2593272776
- Cited by
- 1,027
- References
- 216
- Citations by year
- 2026: 102 · 2025: 99 · 2024: 138 · 2023: 104 · 2022: 105 · 2021: 171 · 2020: 116 · 2019: 89 · 2018: 68 · 2017: 33 · 2013: 1
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Open Research Exeter (University of Exeter) (acceptedVersion)
- Figshare (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- South London and Maudsley NHS Foundation Trust
- National Institute for Health and Care Research
- King's College London
- Institute of Psychiatry, Psychology and Neuroscience, King’s College London
- National Institute of Neurological Disorders and Stroke (P50NS053488)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Parkinson's disease, cognitive decline, Parkinson's disease dementia, mild cognitive impairment, cerebrospinal fluid biomarkers, amyloid-beta 42, Lewy body pathology, APOE ε4, GBA mutations, cognitive training, nootropic drugs
- MeSH terms
- Dementia, Humans, Parkinson Disease, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
